CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies

Ayed O. Ayed, Annalisa Chiappella, Levi Pederson, Betsy R. Laplant, Angela Giovanna Congiu, Gianluca Gaidano, Michele Spina, Alessandro Re, Federica Cavallo, Gerardo Musuraca, William R. MacOn, Thomas Elmer Witzig, Umberto Vitolo, Grzegorz S Nowakowski

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

Original languageEnglish (US)
Article number63
JournalBlood Cancer Journal
Volume8
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Central Nervous System
Recurrence
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP) : Analysis from two phase 2 studies. / Ayed, Ayed O.; Chiappella, Annalisa; Pederson, Levi; Laplant, Betsy R.; Congiu, Angela Giovanna; Gaidano, Gianluca; Spina, Michele; Re, Alessandro; Cavallo, Federica; Musuraca, Gerardo; MacOn, William R.; Witzig, Thomas Elmer; Vitolo, Umberto; Nowakowski, Grzegorz S.

In: Blood Cancer Journal, Vol. 8, No. 7, 63, 01.07.2018.

Research output: Contribution to journalArticle

Ayed, AO, Chiappella, A, Pederson, L, Laplant, BR, Congiu, AG, Gaidano, G, Spina, M, Re, A, Cavallo, F, Musuraca, G, MacOn, WR, Witzig, TE, Vitolo, U & Nowakowski, GS 2018, 'CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies', Blood Cancer Journal, vol. 8, no. 7, 63. https://doi.org/10.1038/s41408-018-0097-0
Ayed, Ayed O. ; Chiappella, Annalisa ; Pederson, Levi ; Laplant, Betsy R. ; Congiu, Angela Giovanna ; Gaidano, Gianluca ; Spina, Michele ; Re, Alessandro ; Cavallo, Federica ; Musuraca, Gerardo ; MacOn, William R. ; Witzig, Thomas Elmer ; Vitolo, Umberto ; Nowakowski, Grzegorz S. / CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP) : Analysis from two phase 2 studies. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 7.
@article{7d5568647b6147df9aa6f4ee4bf36981,
title = "CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies",
abstract = "Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5{\%} of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4{\%} of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7{\%} and an estimated 2-year CNS relapse rate of 0.9{\%} for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0{\%}, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.",
author = "Ayed, {Ayed O.} and Annalisa Chiappella and Levi Pederson and Laplant, {Betsy R.} and Congiu, {Angela Giovanna} and Gianluca Gaidano and Michele Spina and Alessandro Re and Federica Cavallo and Gerardo Musuraca and MacOn, {William R.} and Witzig, {Thomas Elmer} and Umberto Vitolo and Nowakowski, {Grzegorz S}",
year = "2018",
month = "7",
day = "1",
doi = "10.1038/s41408-018-0097-0",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP)

T2 - Analysis from two phase 2 studies

AU - Ayed, Ayed O.

AU - Chiappella, Annalisa

AU - Pederson, Levi

AU - Laplant, Betsy R.

AU - Congiu, Angela Giovanna

AU - Gaidano, Gianluca

AU - Spina, Michele

AU - Re, Alessandro

AU - Cavallo, Federica

AU - Musuraca, Gerardo

AU - MacOn, William R.

AU - Witzig, Thomas Elmer

AU - Vitolo, Umberto

AU - Nowakowski, Grzegorz S

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

AB - Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

UR - http://www.scopus.com/inward/record.url?scp=85049257242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049257242&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0097-0

DO - 10.1038/s41408-018-0097-0

M3 - Article

C2 - 29946110

AN - SCOPUS:85049257242

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 7

M1 - 63

ER -